Literature DB >> 7706740

Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein.

C C Zarozinski1, E F Fynan, L K Selin, H L Robinson, R M Welsh.   

Abstract

Anti-viral CTL were induced in vitro using a particle bombardment device or "gene-gun" to deliver plasmid DNA encoding the nucleoprotein of the lymphocytic choriomeningitis virus (LCMV). Using this plasmid we were able to study T cell-mediated immunity in the absence of a neutralizing Ab response. Upon a single DNA immunization, a nearly 2 log10 reduction in splenic viral titers was observed 3 days after LCMV infection. After two or three immunizations a greater than 3 log10 inhibition of viral titers in the spleen was observed, with most animals having no detectable virus. C57BL/6 mice immunized with DNA encoding the nucleoprotein gene were also challenged with LCMV intracranially. Upon intracranial challenge, vaccinated animals displayed either protection or enhanced immunopathology leading to accelerated kinetics of death. Using limiting dilution analysis it was possible to detect LCMV-specific CTL precursors in both the spleen and lymph nodes of vaccinated animals. C57BL/6 mice inoculated with DNA demonstrated an anamnestic CTL response detectable at day 4 after LCMV challenge. Thus DNA vaccines are capable of inducing an anti-viral T cell response that can inhibit viral replication and mediate either protective immunity or immunopathology. Vaccination with DNA may therefore provide a useful alternative to current viral or subunit vaccines once the efficacy of immunization with DNA is optimized.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706740

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Induction of antiviral antibodies by DNA immunization requires neither perforin-mediated nor CD8(+)-T-cell-mediated lysis of antigen-expressing cells.

Authors:  D E Hassett; J Zhang; J L Whitton
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA.

Authors:  S Oehen; T Junt; C López-Macías; T A Kramps
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

3.  Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization.

Authors:  D E Hassett; J Zhang; M Slifka; J L Whitton
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Intralymphatic immunization enhances DNA vaccination.

Authors:  K J Maloy; I Erdmann; V Basch; S Sierro; T A Kramps; R M Zinkernagel; S Oehen; T M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

5.  DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction.

Authors:  F Rodriguez; J Zhang; J L Whitton
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge.

Authors:  D E Hassett; J Zhang; J L Whitton
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Dendritic cells efficiently induce protective antiviral immunity.

Authors:  B Ludewig; S Ehl; U Karrer; B Odermatt; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

8.  DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.

Authors:  F Rodriguez; L L An; S Harkins; J Zhang; M Yokoyama; G Widera; J T Fuller; C Kincaid; I L Campbell; J L Whitton
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 9.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

10.  A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.

Authors:  Devon J Shedlock; Kendra T Talbott; Christina Cress; Bernadette Ferraro; Steven Tuyishme; Karthik Mallilankaraman; Neil J Cisper; Matthew P Morrow; Stephan J Wu; Omkar U Kawalekar; Amir S Khan; Niranjan Y Sardesai; Karuppiah Muthumani; Hao Shen; David B Weiner
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.